^
Association details:
| Biomarker: | RAS wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) + Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
Published date:
05/25/2023
Excerpt:
The combination of Pmab and Niraparib had an acceptable safety profile, and showed considerable antitumor activity in pts with advanced RAS WT mCRC compared to historical rates.
DOI:
10.1200/JCO.2023.41.16_suppl.3579
Trial ID:
